Chronic Kidney Disease Market size was valued at USD 41 billion in 2024 and is projected to reach USD 82.5 billion by the end of 2037, rising at a CAGR of 6% during the forecast period, i.e., 2025-2037. In 2025, the industry size of chronic kidney disease is evaluated at USD 43.4 billion.
The chronic kidney disease market is witnessing steady growth as the prevalence of CKD rises globally, driven by increasing rates of diabetes, hypertension, and aging populations. Furthermore, the demand for early diagnostic tools and effective treatments is expanding as healthcare providers seek to mitigate disease progression and improve patient outcomes. In July 2023, the European Commission granted approval to Boehringer Ingelheim and Eli Lilly for Jardiance, a drug used to treat chronic kidney disease, further underpinning industry interest in new treatments. Governments and health organizations are also boosting their efforts toward tackling CKD through public awareness campaigns and ensuring better access to its treatment for patients, thus indicating a growth trajectory for the chronic kidney disease market.
Governments worldwide are prioritizing chronic kidney disease care, with initiatives that emphasize early diagnosis and management to reduce the economic and health burden of the disease. In 2023, the diagnosed cases of CKD in the U.S. were reported to stand at 5 million and are likely to increase. In addition, North America and Europe fund research gives access to innovative treatments, further pushing the market. The increasing prevalence of chronic kidney disease, coupled with proactive intervention through governments, opens lucrative growth opportunities for players in the chronic kidney disease market.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6% |
|
Base Year Market Size (2024) |
USD 41 billion |
|
Forecast Year Market Size (2037) |
USD 82.5 billion |
|
Regional Scope |
|
Diagnosis (Blood Test, Urine Test, Imaging Test, and Kidney Biopsy)
Blood tests segment is predicted to account for chronic kidney disease market share of more than 37% by the end of 2037, as they are crucial to the diagnosis of chronic kidney disease through important markers such as the eGFR and creatinine levels. These tests are quite needed in early detection and subsequently in further monitoring due to the fact that clinicians can assess kidney function and disease progression. In March 2022, Nova Biomedical introduced the Nova Max Pro Creatinine/eGFR Meter System to advance point-of-care kidney screenings. This will bridge the gap in the diagnosis of CKD, as blood tests remain an essential prerequisite. Growing utilization of blood testing is thus expected to strengthen the segment's leading position in the market, as health practitioners would seek greater support from these diagnostics in their quest for timely management of disease conditions.
Treatment (Drugs, Dialysis, and Kidney Transplant)
In chronic kidney disease market, drug segment is anticipated to account for revenue share of more than 45% by the end of 2037, due to increasing demand for drugs managing CKD and its comorbidities, like hypertension and diabetes. In September 2023, the FDA granted approval for Jardiance (empagliflozin) for chronic kidney disease treatment, marking a significant advancement in pharmaceutical options. New drugs being introduced further underscore the importance of the segment, as drugs remain an important factor in slowing the progress of CKD and alleviating its symptoms. Ongoing development of targeted therapies supports continued innovation within the drug segment, improving treatment efficacy while widening the choices of chronic kidney disease patients.
Our in-depth analysis of the global market includes the following segments:
|
Diagnosis |
|
|
Treatment |
|
|
Indication |
|
|
End user |
|
North America Market Analysis
North America chronic kidney disease market is set to account for revenue share of more than 42% by the end of 2037, owing to its high prevalence of chronic kidney disease and well-established infrastructure for healthcare services. Due to the high investments in CKD research and campaigns related to raising awareness, North America continues to be one of the largest markets when it comes to diagnosis and treatment options for CKD. The collaboration between public health organizations and private companies is encouraging new forms of treatment, which is driving market growth.
The U.S. chronic kidney disease market is anticipated to be driven by a high prevalence of diabetes and hypertension, favoring conditions for chronic kidney disease. In July 2022, Health Canada accepted GlaxoSmithKline's New Drug Submission for daprodustat which is an oral HIF-PHI for anemia related to underlining that the focus of North America is on advanced treatments. The demand for advanced therapies keeps growing and is reinforcing the U.S. position as one of the leading contributors to the market. The U.S. market also benefits from comprehensive insurance coverage for chronic kidney disease treatments, which allows patients in need to easily access them.
Emphasis on early diagnosis and prevention in the healthcare system propels Canada chronic kidney disease market and supportive governmental healthcare programs. The health authorities in Canada are active in the creation of chronic kidney disease awareness and early treatment, hence increasing demand for diagnostic and treatment services within the country. With this focus in place, Canada supports North America in its commitment to holistic CKD care, which makes it an integral contributor to the regional market. Also, such infrastructural setup for healthcare is firm in Canada, thereby helping early interventionists to push chronic kidney disease patients in most parts of the country.
Asia Pacific Market Analysis
Asia Pacific chronic kidney disease market is expected to grow at more than 5.5% CAGR through 2037, driven by increasing cases of diabetes and healthcare expenditure across the region, particularly in India, China, and Japan. Public health awareness campaigns also create more awareness about chronic kidney disease and its prevention, thus contributing to this region in the market. Most importantly, higher employment toward international firm practices coupled with the development of CKD diagnostics and therapies drives the emergence of the market rapidly across the geographical region.
The chronic kidney disease market in India is rising owing to the increasing incidence of diabetes and a lack of early diagnostics. Bayer launched a finerenone drug in India for chronic kidney disease patients suffering from type 2 diabetes in August 2022, which underpins this growth in demand for accessible treatments. In this respect, this development demonstrates the increasing significance of CKD care in India, where timely intervention and treatment options are incredibly important. In addition, government-backed programs to help improve rural healthcare access will continue to support growth in this market segment.
Government-driven healthcare reforms in China and growing awareness of kidney health supplement the growth of the chronic kidney disease market in the region. In May 2024, Everest Medicines launched a delayed-release capsule, Nefecon, for IgA nephropathy, one of the most common subtypes of chronic kidney disease in China. The launch indicates that the country is paying attention to the therapies for CKD, favoring regional market growth. Furthermore, the Chinese government is highly investing in healthcare technologies and infrastructures, facilitating access to innovative CKD therapies.
The chronic kidney disease market is fiercely competitive with leading players such as Abbott, Siemens, Beckman Coulter, F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc., Nova Biomedical, AstraZeneca, GlaxoSmithKline Plc, and Bayer AG-the better-known leaders in the industry. These companies develop diagnostic and pharmaceutical solutions to improve chronic kidney disease care while creating a market presence through R&D, partnerships, and product launches. As chronic kidney disease prevalence further increases in the world, companies put a huge amount of money into innovative solutions for treatment and market expansion.
In September 2023, Fresenius Medical Care was granted FDA breakthrough device designation for its hemodialysis machine, a further indication of how the competition within the landscape pivots on advanced technology with respect to dialysis. This also underlines the continued commitment of leading companies in driving innovation inside CKD care through solutions that promote better patient outcomes coupled with seamless treatments. The intensity in competition among leading companies is propelled by advancements in CKD treatment and diagnostics, improving the quality of life among chronic kidney disease patients worldwide
Here are some leading players in the chronic kidney disease market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?